乳腺癌新辅助化疗进展

被引：18

作者：

王义民

郭宝良

机构：

[1] 哈尔滨医科大学第二附属医院乳腺外科

来源：

中国普通外科杂志 | 2014年 / 23卷 / 11期

关键词：

乳腺肿瘤; 新辅助化疗; 综述文献;

D O I：

暂无

中图分类号：

R737.9 [乳腺肿瘤];

学科分类号：

100214 [肿瘤学];

摘要：

新辅助化疗是乳腺癌全身治疗重要的部分,但在如何选择高效的化疗药物、制定个体化治疗方案、预测治疗效果仍需进一步研究。笔者将从新辅助化疗的意义和适应人群、病理完全缓解作为预后指标的标记物、药物和方案的选择、不同分子分型的新辅助化疗4个方面进行综述。

引用

页码：1561 / 1566

页数：6

共 8 条

[1]

三阴性乳腺癌的临床病理特征分析 [J].

钱宏美 ;

张亚男 ;

张勇 ;

嵇振岭 .

中国普通外科杂志, 2011, 20 (11) :1196-1198

[2]

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial [J].

von Minckwitz, Gunter ;

Schneeweiss, Andreas ;

Loibl, Sibylle ;

Salat, Christoph ;

Denkert, Carsten ;

Rezai, Mahdi ;

Blohmer, Jens U. ;

Jackisch, Christian ;

Paepke, Stefan ;

Gerber, Bernd ;

Zahm, Dirk M. ;

Kummel, Sherko ;

Eidtmann, Holger ;

Klare, Peter ;

Huober, Jens ;

Costa, Serban ;

Tesch, Hans ;

Hanusch, Claus ;

Hilfrich, Joern ;

Khandan, Fariba ;

Fasching, Peter A. ;

Sinn, Bruno V. ;

Engels, Knut ;

Mehta, Keyur ;

Nekljudova, Valentina ;

Untch, Michael .

LANCET ONCOLOGY, 2014, 15 (07) :747-756

[3]

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial [J].

Gianni, Luca ;

Pienkowski, Tadeusz ;

Im, Young-Hyuck ;

Roman, Laslo ;

Tseng, Ling-Ming ;

Liu, Mei-Ching ;

Lluch, Ana ;

Staroslawska, Elzbieta ;

de la Haba-Rodriguez, Juan ;

Im, Seock-Ah ;

Pedrini, Jose Luiz ;

Poirier, Brigitte ;

Morandi, Paolo ;

Semiglazov, Vladimir ;

Srimuninnimit, Vichien ;

Bianchi, Giulia ;

Szado, Tania ;

Ratnayake, Jayantha ;

Ross, Graham ;

Valagussa, Pinuccia .

LANCET ONCOLOGY, 2012, 13 (01) :25-32

[4]

Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study.[J]..Breast Cancer Research and Treatment.2010, 1

[5]

Management of triple negative breast cancer [J].

Oakman, Catherine ;

Viale, Giuseppe ;

Di Leo, Angelo .

BREAST, 2010, 19 (05) :312-321

[6]

A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancer [J].

Colleoni, Marco ;

Bagnardi, Vincenzo ;

Rotmensz, Nicole ;

Viale, Giuseppe ;

Mastropasqua, Mauro ;

Veronesi, Paolo ;

Cardillo, Anna ;

Torrisi, Rosalba ;

Luini, Alberto ;

Goldhirsch, Aron .

EUROPEAN JOURNAL OF CANCER, 2010, 46 (12) :2216-2224

[7]

Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting.[J].Marco Colleoni;Giuseppe Viale;Aron Goldhirsch.The Breast.2009,

[8]

Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93 [J].

Thuerlimann, Beat ;

Price, Karen N. ;

Gelber, Richard D. ;

Holmberg, Stig B. ;

Crivellari, Diana ;

Colleoni, Marco ;

Collins, John ;

Forbes, John F. ;

Castiglione-Gertsch, Monica ;

Coates, Alan S. ;

Goldhirsch, Aron .

BREAST CANCER RESEARCH AND TREATMENT, 2009, 113 (01) :137-144

← 1 →